Cytoskeletal protein carbonylation and degradation in experimental autoimmune encephalomyelitis

Journal of Neurochemistry

Volumn 105, Issue 3, 2008, Pages 763-772

  Smerjac, Suzanne M ^a   Bizzozero, Oscar A ^a,b  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Cytoskeletal degradation; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Oxidative stress; Protein carbonylation

Indexed keywords

2,4 DINITROPHENYLHYDRAZINE; BETA ACTIN; BETA TUBULIN; CYTOSKELETON PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTATHIONE; NEUROFILAMENT PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; LIPID PEROXIDATION; MALE; MULTIPLE SCLEROSIS; NERVE FIBER; NONHUMAN; OXIDATIVE STRESS; PERIKARYON; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEIN DEGRADATION; RAT; WESTERN BLOTTING;

ACTINS; ANIMALS; AXONS; CYTOSKELETAL PROTEINS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTATHIONE; LIPID PEROXIDATION; MALE; MULTIPLE SCLEROSIS; MYELITIS; NEUROFILAMENT PROTEINS; NEURONS; OXIDATIVE STRESS; PROTEIN CARBONYLATION; RATS; RATS, INBRED LEW; SPINAL CORD; WALLERIAN DEGENERATION;

RATTUS;

EID: 42449141602     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2007.05178.x     Document Type: Article

References (55)

1. Aksenov M. Y., Aksenova M. V., Butterfield D. A., Geddes J. W. Markesbery W. R. (2001) Protein oxidation in the brain in Alzheimer's disease. Neuroscience 103, 373 383.
2. Aldini G., Dalle-Donne I., Facino R. M., Milzani A. Carini M. (2006) Intervention strategies to inhibit protein carbonylation by lipoxidation-derived reactive carbonyls. Med. Res. Rev. 27, 817 868.
3. Aquino D. A., Chiu F. C., Brosnan C. F. Norton W. T. (1988) Glial fibrillary acidic protein increases in the spinal cord of Lewis rats with acute experimental autoimmune encephalomyelitis. J. Neurochem. 51, 1085 1096.
4. Banan A., Fitzpatrick L., Zhang Y. Keshavarzian A. (2001) OPC-compounds prevent oxidant-induced carbonylation and depolymerization of the F-actin cytoskeleton and intestinal barrier hyperpermeability. Free Radic. Biol. Med. 30, 287 298.
5. Banan A., Zhang L. J., Shaikh M., Fields J. Z., Farhadi A. Keshavarzian A. (2004) Novel effect of NF-kappaB activation: carbonylation and nitration injury to cytoskeleton and disruption of monolayer barrier in intestinal epithelium. Am. J. Physiol. Cell Physiol. 287, C1139 C1151.
6. Berlett B. S. Stadtman E. R. (1997) Protein oxidation in aging, disease, and oxidative stress. J. Biol. Chem. 272, 20313 20316.
7. Bizzozero O. A. (2007) Major cytoskeletal proteins are carbonylated in multiple sclerosis, in ISN-Satellite Meeting on Myelin Development and Function (Macklin W., ed pp. 33. Chichen Itza, Mexico.
8. Bizzozero O. A., DeJesus G., Callahan K. Pastuszyn A. (2005) Elevated protein carbonylation in the brain white matter and gray matter of patients with multiple sclerosis. J. Neurosci. Res. 81, 687 695.
9. Bizzozero O. A., Ziegler J. L., De Jesus G. Bolognani F. (2006) Acute depletion of reduced glutathione causes extensive carbonylation of rat brain proteins. J. Neurosci. Res. 83, 656 667.
10. Bizzozero O. A., Reyes S., Ziegler J. Smerjac S. (2007) Lipid peroxidation scavengers prevent the carbonylation of cytoskeletal brain proteins induced by glutathione depletion. Neurochem. Res. 32, 2114 2122.
11. Dalle-Donne I., Rossi R., Giustarini D., Gagliano N., Lusini L., Milzani A., Di Simplicio P. Colombo R. (2001) Actin carbonylation: from a simple marker of protein oxidation to relevant signs of severe functional impairment. Free Radic. Biol. Med. 31, 1075 1083.
12. Dalle-Donne I., Giustarini D., Colombo R., Rossi R. Milzani A. (2003) Protein carbonylation in human diseases. Trends Mol. Med. 9, 169 176.
13. Dalle-Donne I., Aldini G., Carini M., Colombo R., Rossi R. Milzani A. (2006) Protein carbonylation, cellular dysfunction, and disease progression. J. Cell. Mol. Med. 10, 389 406.
14. Davies K. J. Shringarpure R. (2006) Preferential degradation of oxidized proteins by the 20S proteasome may be inhibited in aging and in inflammatory neuromuscular diseases. Neurology 66, S93 S96.
15. Day M. (2005) Histopathology of EAE, in Experimental Models of Multiple Sclerosis (Lavi E. Constantinescu C., eds pp. 25 43. Springer, NY.
16. Esterbauer H., Schaur R. J. Zollner H. (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 11, 81 128.
17. Ferrante R. J., Browne S. E., Shinobu L. A., Bowling A. C., Baik M. J., MacGarvey U., Kowall N. W., Brown R. H. Beal M. F. (1997) Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J. Neurochem. 69, 2064 2074.
18. Floor E. Wetzel M. G. (1998) Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J. Neurochem. 70, 268 275.
19. Friguet B., Szweda L. I. Stadtman E. R. (1994) Susceptibility of glucose-6-phosphate dehydrogenase modified by 4-hydroxy-2-nonenal and metal-catalyzed oxidation to proteolysis by the multicatalytic protease. Arch. Biochem. Biophys. 311, 168 173.
20. Gelinas S., Chapados C., Beauregard M., Gosselin I. Martinoli M. G. (2000) Effect of oxidative stress on stability and structure of neurofilament proteins. Biochem. Cell Biol. 78, 667 674.
21. Gilgun-Sherki Y., Melamed E. Offen D. (2004) The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J. Neurol. 251, 261 268.
22. Gold R., Hartung H. P. Toyka K. V. (2000) Animal models for autoimmune demyelinating disorders of the nervous system. Mol. Med. Today 6, 88 91.
23. Grune T., Reinheckel T., Joshi M. Davies K. J. (1995) Proteolysis in cultured liver epithelial cells during oxidative stress. Role of the multicatalytic proteinase complex, proteasome. J. Biol. Chem. 270, 2344 2351.
24. Grune T., Reinheckel T. Davies K. J. (1997) Degradation of oxidized proteins in mammalian cells. FASEB J. 11, 526 534.
25. Guyton M. K., Sribnick E. A., Wingrave J. M., Ray S. K. Banik N. L. (2005) Axonal damage and neuronal death in multiple sclerosis and experimental autoimmune encephalomyelitis: the role of calpain, in Multiple Sclerosis as a Neuronal Disease (Waxman S., ed pp. 293 303. Elsevier, NY.
26. Hassen G. W., Feliberti J., Kesner L., Stracher A. Mokhtarian F. (2006) A novel calpain inhibitor for the treatment of acute experimental autoimmune encephalomyelitis. J. Neuroimmunol. 180, 135 146.
27. Hosseini H., Andre P., Lefevre N., Viala L., Walzer T., Peschanski M. Lotteau V. (2001) Protection against experimental autoimmune encephalomyelitis by a proteasome modulator. J. Neuroimmunol. 118, 233 244.
28. Kalman B., Laitinen K. Komoly S. (2007) The involvement of mitochondria in the pathogenesis of multiple sclerosis. J. Neuroimmunol. 188, 1 12.
29. Lee M. H., Hyun D. H., Jenner P. Halliwell B. (2001) Effect of proteasome inhibition on cellular oxidative damage, antioxidant defences and nitric oxide production. J. Neurochem. 78, 32 41.
30. LeVine S. M. (1992) The role of reactive oxygen species in the pathogenesis of multiple sclerosis. Med. Hypotheses 39, 271 274.
31. Li Y. Black M. M. (1996) Microtubule assembly and turnover in growing axons. J. Neurosci. 16, 531 544.
32. Muntane G., Daldo E., Martinez A., Rey M. J., Avila J., Perez M., Portero M., Pamplona R., Ayala V. Ferrer I. (2006) Glial fibrillary acidic protein is a major target of glycoxidative and lipoxidative damage in Pick's disease. J. Neurochem. 99, 177 185.
33. Neely M. D., Boutte A., Milatovic D. Montine T. J. (2005) Mechanisms of 4-hydroxynonenal-induced neuronal microtubule dysfunction. Brain Res. 1037, 90 98.
34. Nie C. L., Wei Y., Chen X., Liu Y. Y., Dui W., Liu Y., Davies M. C., Tendler S. J. He R. G. (2007) Formaldehyde at low concentration induces protein tau into globular amyloid-like aggregates in vitro and in vivo. PLoS ONE 2, e629.
35. Nixon R. A. Logvinenko K. B. (1986) Multiple fates of newly synthesized neurofilament proteins: evidence for a stationary neurofilament network distributed nonuniformly along axons of retinal ganglion cell neurons. J. Cell Biol. 102, 647 659.
36. Nystrom T. (2005) Role of oxidative carbonylation in protein quality control and senescence. EMBO J. 24, 1311 1317.
37. Ohkawa H., Ohishi N. Yagi K. (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95, 351 358.
38. Ozeki M., Miyagawa-Hayashino A., Akatsuka S., Shirase T., Lee W. H., Uchida K. Toyokuni S. (2005) Susceptibility of actin to modification by 4-hydroxy-2-nonenal. J. Chromatogr. 827, 119 126.
39. Pacifici R. E., Kono Y. Davies K. J. (1993) Hydrophobicity as the signal for selective degradation of hydroxyl radical-modified hemoglobin by the multicatalytic proteinase complex, proteasome. J. Biol. Chem. 268, 15405 15411.
40. Reth M. (2002) Hydrogen peroxide as second messenger in lymphocyte activation. Nat. Immunol. 3, 1129 1134.
41. Riddles P. W., Blakeley R. L. Zerner B. (1979) Ellman's reagent: 5,5′-dithiobis(2-nitrobenzoic acid) - a reexamination. Anal. Biochem. 94, 75 81.
42. Rivett A. J. (1985) Preferential degradation of the oxidatively modified form of glutamine synthetase by intracellular mammalian proteases. J. Biol. Chem. 260, 300 305.
43. Sagara Y. Schubert D. (1998) The activation of metabotropic glutamate receptors protects nerve cells from oxidative stress. J. Neurosci. 18, 6662 6671.
44. Sayre L. M., Moreira P. I., Smith M. A. Perry G. (2005) Metal ions and oxidative protein modification in neurological disease. Ann. Ist. Super. Sanita. 41, 143 164.
45. Schaecher K., Rocchini A., Dinkins J., Matzelle D. D. Banik N. L. (2002) Calpain expression and infiltration of activated T cells in experimental allergic encephalomyelitis over time: increased calpain activity begins with onset of disease. J. Neuroimmunol. 129, 1 9.
46. Shacter E. (2000) Quantification and significance of protein oxidation in biological samples. Drug Metab. Rev. 32, 307 326.
47. Shields D. C. Banik N. L. (1998) Upregulation of calpain activity and expression in experimental allergic encephalomyelitis: a putative role for calpain in demyelination. Brain Res. 794, 68 74.
48. Shringarpure R., Grune T. Davies K. J. (2001) Protein oxidation and 20S proteasome-dependent proteolysis in mammalian cells. Cell Mol. Life Sci. 58, 1442 1450.
49. Smerjac S. Bizzozero O. A. (2006) Evidence for increased protein carbonylation in experimental autoimmune encephalomyelitis. J. Neurochem. 96 (Suppl. 1 132.
50. Smerjac S. Bizzozero O. A. (2007) Cytoskeletal degradation and oxidation in experimental autoimmune encephalomyelits. J. Neurochem. 102 (Suppl. 1 226.
51. Smith M. A., Rudnicka-Nawrot M., Richey P. L., Praprotnik D., Mulvihill P., Miller C. A., Sayre L. M. Perry G. (1995) Carbonyl-related posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer's disease. J. Neurochem. 64, 2660 2666.
52. Stadtman E. R. (1990) Covalent modification reactions are marking steps in protein turnover. Biochemistry 29, 6323 6331.
53. Troncoso J. C., Costello A. C., Kim J. H. Johnson G. V. (1995) Metal-catalyzed oxidation of bovine neurofilaments in vitro. Free Radic. Biol. Med. 18, 891 899.
54. Vanderlugt C. L., Rahbe S. M., Elliott P. J., Del Canto M. C. Miller S. D. (2000) Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. J. Autoimmun. 14, 205 211.
55. Vitvitsky V., Thomas M., Ghorpade A., Gendelman H. E. Banerjee R. (2006) A functional trans-sulfuration pathway in the brain links to glutathione homeostasis. J. Biol. Chem. 281, 35785 35793.